Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...

Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

Eli Lilly (NYSE: LLY) has received a positive recommendation for approval from European regulators for its drug Omvoh in the ...

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $789.12 which represents a slight increase of $6.77 or 0.87% from the prior close of $782.35. The stock opened at $777.13 and ...

Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...